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Abstract 
Introduction: This observational study aimed to assess the effectiveness of lixisenatide as add on therapy to basal 
insulin in diabetic type 2 patients previously treated with different insulin regimes.
Methods: Patients with diabetes type 2, prescribed with lixisenatide and basal insulin were divided in three groups 
(premixed insulin, basal bolus insulin and basal oral therapy (BOT). Difference in mean change in HbA1c, body 
mass index, total insulin doses, fasting blood glucose (FPG) and prandial blood glucose (PPG) were assessed after 
3–6‑months of follow‑up.
Results: The primary outcomes were assessed in 111 patients. Lixisenatide added to basal insulin, reduced HbA1c 
and body weight significantly in all three groups of patients (p < 0.001 for all), with the most prominent reduction 
in the basal bolus group of patients which had the highest baseline HbA1c compared to premix and BOT treat‑
ment groups. Regarding a difference in total insulin dose the reduction was statistically significant in the basal bolus 
(p = 0.006) and premix group (p < 0.001). FPG and PPG were also significantly reduced over time in all three groups 
(p < 0.001 for all). A composite outcome (reduction of HbA1c below 7% (53 mmol/mol) with any weight loss) was 
achieved in 27% of total patients included in the study, reduction of HbA1c below 7% was observed in 30% of 
patients, while 90% of patients experienced weight reduction.
Conclusion: These results indicate that lixisenatide add on basal insulin treatment (BIT) can improve glycemic con‑
trol in a population with long‑standing type 2 diabetes and previously uncontrolled on other insulin therapy.
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Introduction
Type 2 diabetes is designated by a chronic progressive 
course and a subsequent need for a long-term insu-
lin therapy to achieve optimal glucose control. Still, a 
substantial number of T2DM patients do not achieve 
optimal glucose control despite intensive insulin treat-
ment [1, 2].
Strong rationale exists for the usage of basal insulin in 
combination with treatments that address postprandial 
glucose, in order to achieve target HbA1c. In comparison 
to the previous options, when the basal insulin regime 
was intensified by adding short-acting insulin, today add-
ing GLP-1 RA to basal insulin represents alternative to 
adding prandial insulin [3–5].
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Although lixisenatide as add on therapy to basal insu-
lin has demonstrated equal efficacy as basal bolus insu-
lin therapy in a head-to-head clinical trial [6], real-world 
evidence of comparative effectiveness is lacking. The aim 
of this observational study was to assess the effectiveness 
of lixisenatide as an add on therapy to basal insulin in 
diabetic type 2 patients previously treated with different 
insulin regimes in real world setting.
Patients and methods
Patients
This was a multicenter observational study conducted 
at five tertiary and secondary hospital centers in Croa-
tia (Zagreb, Osijek, Split and Čakovec). Patients were 
recruited from diabetes outpatient clinics and data from 
electronic medical records were taken retrospectively 
and analyzed starting from 2014 until 2017 since lixi-
senatide has become available in Croatia in May 2014. 
The study included 111 patients (43 male, 68 female), 
diagnosed with type 2 diabetes aged 20–80  years, inad-
equately controlled (HbA1c level ≥ 7 (53 mmol/mol) and 
≤ 11% (97 mmol/mol)) on different insulin regimes; pre-
mix insulin analogues (45%), basal-bolus regimen (13.5%) 
or basal supported oral therapy (41.4%). All subjects were 
GLP 1 RA naïve and consequently prescribed lixisenatide 
and basal insulin for at least 3–6 months.
This study complied with the Declaration of Helsinki 
and was approved by the ethics committees. Informed 
consent was obtained from all patients included in the 
study.
Clinical measurements
The following data were collected at baseline and follow 
up visits (after 3–6  months); age, duration of diabetes, 
sex, diabetic medications, HbA1c, weight, height, BMI, 
fasting and postprandial blood glucose levels. Changes 
in HbA1c, fasting blood glucose, postprandial blood glu-
cose, weight, BMI, were assessed and analyzed. The pri-
mary study endpoint was the proportion of participants 
achieving HbA1c < 7.0% (53  mmol/mol) and/or body 
weight reduction. Secondary endpoint included changes 
in insulin doses, FPG and PPG.
Statistical analysis
Descriptive statistics was used to describe baseline char-
acteristics of the study sample (proportions for categori-
cal data, and mean ± standard deviation for normally 
distributed continuous variables). Categorical variables 
of composite outcomes (reduction in weight gain and 
HbA1c) between three groups according to regimen 
were analyzed with Chi square test. Two-way repeated-
measures ANOVA were used to determine change in 
given parameters over follow-up period, regarding three 
groups of patients (with Scheffe’s post hoc test, and Bon-
ferroni correction for multiple comparisons). All statisti-
cal comparisons are two-tailed and they were considered 
significant at the p < 0.05.
Results
The primary outcome was assessed in 111 patients, 43 
(38.7%) males and 68 (61.3%) females.
Subjects’ characteristics at baseline and after follow 
up period of 3–6 months are presented in Table 1. Aver-
age duration of diabetes was 9.6 ± 5.7 years, average age 
of participants was 62.9 ± 9.4  years and median insulin 
treatment duration was 20 months. Majority of patients 
applied basal insulin in the evening 78 (73.7%), while 
lixisenatide was administered prior breakfast or lunch in 
equal proportion (43.6% vs. 53.6%).
In the group of patients previously treated with premix 
insulins average age of patients was 67.4 years with aver-
age duration of diabetes 12.6  years as opposed to basal 
bolus and basal oral therapy with average age of patients 
58.5 and 59.4 years and average duration of diabetes 6.8 
and 7.8 years respectively.
Lixisenatide added to basal insulin, reduced HbA1c 
significantly in all three groups of patients (p < 0.001 for 
all), with the most prominent reduction in the basal bolus 
group of patients. (p < 0.001; 2% reduction vs. 0.6 and 
0.8% reduction in premix and BOT group respectively) 
which had the highest baseline HbA1c compared to pre-
mix and BOT treatment groups (9.6 ± 1.8% vs. 8.4 ± 1.2 
and 8.5 ± 0.9) Fig. 1.
The average body weight of the subjects significantly 
decreased over time (p < 0.001) in all three groups. The 
greatest decrease occurred in the basal bolus group with 
smaller decline in the other two groups (p = 0.003) Fig. 1.
Regarding a difference in total insulin dose the reduc-
tion was statistically significant in the basal bolus 
(p = 0.006) and premix group (p < 0.001), but not in the 
basal oral therapy group where a slight increase in the 
average dose of basal insulin was noted. Dose of basal 
insulin did not change significantly from baseline to fol-
low up visit.
FPG and PPG were also significantly reduced over time 
in all three groups (p < 0.001 for all). Smallest reduction in 
FPG occurred in the basal oral therapy group (p = 0.009), 
while there were no significant differences in PPG reduc-
tion between groups.
A composite outcome (reduction of HbA1c below 7% 
(53  mmol/mol) with any weight loss) was achieved in 
27% of total patients included in the study, reduction of 
HbA1c below 7% (53 mmol/mol) was observed in 30% of 
patients, while 90% of patients experienced weight reduc-
tion (Table  2). Largest proportion of patients achiev-
ing composite outcome was in premix group (13.5%) 
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followed by BOT (9%) and basal bolus group (4.5%), If we 
look at the reduction of HbA1c below 7% (53 mmol/mol) 
alone then similar distribution among the groups was 
observed. In addition, decrease of body weight was noted 
in 90% of patients, majority of them being in premix and 
BOT groups followed by basal bolus. However, difference 
for each outcome was not statistically significant among 
different groups.
Discussion
Meta-analysis of 15 studies demonstrated that the com-
bination of GLP-1 RA and basal insulin, in comparison 
with other anti-diabetic treatments, can enable achieve-
ment of robust glycemic control, without increased risk 
of hypoglycemia and weight gain [7].
Our results are in agreement with GetGoal-L and GG-
Duo1 randomized clinical trials (RCT) [8, 9]. In both 
studies lixisenatide led to a significant decrease in HbA1c 
up to − 0.7%, lowered body weight and was associated 
with lower insulin dose. In conclusion, lixisenatide could 
be considered as an alternative to prandial insulin in 
T2DM patients sub-optimally controlled on basal insulin 
which is now supported with real life data.
The GetGoal Duo 2 study is the first trial to directly 
compare lixisenatide with prandial insulin in combi-
nation with basal insulin [6]. The results of the study 
showed that lixisenatide brings the combined benefit of 
HbA1c management in line with bolus insulins but with 
weight reduction as opposed to the usual weight gain and 
with lower risk of hypoglycemia and lower total insulin 
dose. Similarly, results of the LIRA-ADD2BASAL study 
where liraglutide was added to preexisting basal insulin, 
showed significantly more patients within glycemic tar-
gets with addition of this long acting GLP1-RA, and also 
higher proportion of patients reaching composite end-
points, with additional weight reduction and low hypo-
glycemia risk [10]. Recently published data on DUAL 
VII RCT showed superior results of fixed combination 
of IDegLira compared to basal-bolus insulin regimen in 
risk of hypoglycemia and weight at comparable glycemic 
control [11], bringing the combination of GLP1-RA and 
basal insulin in the spot light of treatment intensification 
of T2DM.
In our real-life study, we have provided evidence 
of additional benefits besides weight reduction and 
decrease in total insulin doses such as significant reduc-
tion in HbA1c in majority of patients. Furthermore, this 
combination is interesting also due to the pathophysi-
ological background of DMT2, while beta-cell function is 
severely impaired in progressed DMT2, and short acting 
glucagon-like peptide-1 receptor agonists (GLP1-RA) has 
a pronounced effect on GIT motility [12].
It is evident that insulin initiation is delayed with multi-
ple oral antidiabetic (OAD) combinations, but one of the 
biggest challenge in clinical practice especially in Croa-
tia are sub-optimally regulated premix and basal bolus 
Table 1 Comparison of data obtained at baseline and after 3–6 months of follow up in all three groups of patients
BMI body mass index, FPG fasting plasma glucose, PPG postprandial plasma glucose
Type of insulin regime (n) Parameters Baseline Control visit p value
Mean ± SD Mean ± SD
Premix (50) Weight (kg) 104 ± 14 99 ± 13  0.003
BMI (kg/m2) 38.1 ± 3.1 36.0 ± 3.1  0.039
Total daily insulin (IU) 53 ± 21 41 ± 12 < 0.001
Hba1c (%) 8.4 ± 1.2 7.6 ± 0.9 < 0.001
FBG (mmol/l) 10.1 ± 2.4 7.7 ± 1.8 < 0.001
PPG (mmol/l) 10.8 ± 2.5 8.7 ± 2 < 0.001
Basal oral (46) Weight (kg) 109 ± 12 104 ± 11  0.003
BMI (kg/m2) 38.7 ± 3.3 38.6 ± 10 NS
Total daily insulin (IU) 35 ± 14 37 ± 11 NS
Hba1c (%) 8.5 ± 0.9 7.6 ± 0.7 < 0.001
FBG (mmol/l) 8.3 ± 2.4 7.2 ± 1.6  0.009
PPG (mmol/l) 11.4 ± 2.1 8.4 ± 1.7 < 0.001
Basal bolus (15) Weight (kg) 107 ± 19 98 ± 14 < 0.001
BMI (kg/m2) 36.0 ± 1 33.8 ± 1.1  0.039
Total daily insulin (IU) 71 ± 27 50 ± 24  0.006
Hba1c (%) 9.6 ± 1.8 7.5 ± 0.9 < 0.001
FBG (mmol/l) 10.3 ± 3 7.6 ± 1.4 < 0.001
PPG (mmol/l) 12.4 ± 2.9 9.2 ± 2.5 < 0.001
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patients who often come with the problems of hypogly-
cemia and weight gain. In addition, health reimburse-
ment restrictions for GLP1-RA in Croatia (BMI > 35) 
reduces the pool of potential patients for GLP1 therapy 
[13]. However, according to our data those patients with 
BMI over 35 kg/m2 treated with different insulin regimes 
regardless of baseline HbA1c level and duration of dia-
betes could benefit from this specific combination with 
regard to not only weight and hypoglycemia reduction, 
but also HbA1c improvement. The biggest success of this 
change in treatment was noted in patients treated with 
premix insulins.
The main limitation of this study is non-interventional 
observational design and availability of only routine data. 
Also, some clinical events such as hypoglycemic episodes 
were omitted or underreported which disabled analysis 
Fig. 1 Change of HbA1c and body weight over a follow up period of 3–6 months
Table 2 Assesment of outcomes according to groups 
and total number of patients
BMI body mass index, NS not significant
Type of insulin regime Outcome n % p value
Premix Decrease in both BMI and 
HbA1c < 7%
15 13.5
Decrease in body weight 45 40.9 NS
Decrease in HbA1c < 7 16 14.5
Basal Decrease in both BMI and 
HbA1c < 7%
10 9
Decrease in body weight 39 35.5 NS
Decrease in HbA1c < 7 13 11.8
Basal bolus Decrease in both BMI and 
HbA1c < 7%
5 4.5
Decrease in body weight 15 13.5 NS
Decrease in HbA1c < 7 5 4.5
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of those data. The strength lays in the uniqueness of data 
presented since no real life data exist regarding lixisena-
tide in combination with basal insulin, especially not in 
previously insulin treated patients.
Conclusion
Our results indicate and confirm RCT data that lixisena-
tide add on basal insulin treatment can improve glycemic 
control in a population with long-standing type 2 diabe-
tes and previously uncontrolled on other insulin thera-
peutic modalities.
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